1] Shastry B S. Parkinson disease:Etiology, pathogenesis and future of gene therapy[J]. Neuroscience Research, 2001, 41(1):5-12.
[2] Chase T N, Oh J D, Blanchet P J. Neostriatal mechanisms in parkinson's disease[J]. Neurology, 1998, 51(Suppl 2):S30-35.
[3] Hu G, Jousilahti P, Bidel S, et al. Type 2 diabetes and the risk of parkinson's disease[J]. Diabetes Care, 2007, 30(4):842-847.
[4] Driver J A, Smith A, Buring J E, et al. Prospective cohort study of type 2 diabetes and the risk of parkinson's disease[J]. Diabetes Care, 2008, 31 (10):2003-2005.
[5] Xu Q, Park Y, Huang X, et al. Diabetes and risk of parkinson's disease[J]. Diabetes Care, 2011, 34(4):910-915.
[6] Cereda E, Barichella M, Pedrolli C, et al. Diabetes and risk of parkinson's disease[J]. Movement Disorders, 2013, 28(2):257.
[7] Cereda E, Barichella M, Pedrolli C, et al. Diabetes and risk of parkinson's disease:A systematic review and meta-analysis[J]. Diabetes Care, 2011, 34(12):2614-2623.
[8] Choi J Y, Jang E H, Park C S, et al. Enhanced susceptibility to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine neurotoxicity in high-fat dietinduced obesity[J]. Free Radical Biology and Medicine, 2005, 38(6):806-816.
[9] Morris J K, Bomhoff G L, Stanford J A, et al. Neurodegeneration in an animal model of parkinson's disease is exacerbated by a high-fat diet[J]. American Journal of Physiology-regulatory Integrative and Comparative Physiology, 2010, 299(4):1082-1090.
[10] Santiago J A, Potashkin J A. Sha red dysregulated pathways lead to parkinson's disease and diabetes[J]. Trends in Molecular Medicine, 2013, 19(3):176-186.
[11] Palacios N, Ascherio A. Reply to:Diabetes and risk of parkinson's disease[J]. Movement Disorders, 2013, 28(2):258.
[12] Deng Y, Zhang Y, Li Y, et al. Occurrence and distribution of salsolinollike compound, 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (adtiq) in parkinsonian brains[J]. Journal of Neural Transmission, 2012, 119(4):435-441.
[13] Xie B, Lin F, Ullah K, et al. A newly discovered neurotoxin adtiq associated with hyperglycemia and parkinson's disease[J]. Biochemical and Biophysical Research Communications, 2015, 459(3):361-366.
[14] Kikuchi S, Shinpo K, Moriwaka F, et al. Neurotoxicity of methylglyoxal and 3-deoxyglucosone on cultured cortical neurons:Synergism between glycation and oxidative stress, possibly involved in neurodegenerative diseases[J]. Journal of Neuroscience Research, 1999, 57(2):280-289.
[15] Shinpo K, Kikuchi S, Sasaki H, et al. Selective vulnerability of spinal motor neurons to reactive dicarbonyl compounds, intermediate products of glycation, in vitro:Implication of inefficient glutathione system in spinal motor neurons[J]. Brain Research, 2000, 861(1):151-159.
[16] Lu J, Randell E, Han Y, et al. Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy[J]. Clinical Biochemistry, 2011, 44(4):307-311.
[17] Vander D L. Methylglyoxal, diabetes mellitus and diabetic complications[J]. Drug Metabolism and Drug Interactions, 2008, 23(1/2):93-124.
[18] Turk Z, Nemet I, Varga L, et al. Elevated level of methylglyoxal during diabetic ketoacidosis and its recovery phase[J]. Diabetes & Metabolism, 2006, 32(2):176-180.
[19] Hipkiss A R. Aging risk factors and parkinson's disease:Contrasting roles of common dietary constituents[J]. Neurobiology of Aging, 2014, 35 (6):1469-1472.
[20] Alan R. Parkinson's disease and type-2 diabetes:Methylglyoxal may be a common causal agent; carnosine could be protective[J/OL]. Molecular Medicine & Therapeutics[2015-07-02]. http://mattitolonen.fi/files/pdf/Hipkiss_2013.pdf.
[21] Burke W J, Li S W, Chung H D, et al. Neurotoxicity of mao metabolites of catecholamine neurotransmitters:Role in neurodegenerative diseases[J]. Neurotoxicology, 2004, 25(1/2):101-115.
[22] Stokes A H, Hastings T G, Vrana K E. Cytotoxic and genotoxic potential of dopamine[J]. Journal of Neuroscience Research, 1999, 55(6):659-665.
[23] Kitayama S, Wang J B, Uhl G R. Dopamine transporter mutants selectively enhance mpp+ transport[J]. Synapse, 1993, 15(1):58-62.
[24] Boada J, Cutillas B, Roig T, et al. Mpp(+)-induced mitochondrial dysfunction is potentiated by dopamine[J]. Biochemical and Biophysical Research Communications, 2000, 268(3):916-920.
[25] Song D W, Xin N, Xie B J, et al. Formation of a salsolinol-like compound, theneurotoxin,1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, in a cellular model of hyperglycemia and a rat model of diabetes[J]. International Journal of Molecular Medicine, 2014, 33(3):736-742.
[26] Morris J K, Bomhoff G L, Gorres B K, et al. Insulin resistance impairs nigrostriatal dopamine function[J]. Experimental Neurology, 2011, 231 (1):171-180.
[27] Schultz W. Getting formal with dopamine and reward[J]. Neuron, 2002, 36(2):241-263.
[28] Xie B, Lin F, Peng L, et al. Methylglyoxal increased dopamine level and led to oxidative stress in sh-sy5y cells[J]. Acta Biochimica et Biophysica Sinica, 2014, 46(11):950-956.
